Related Experiment Video For TSC2 mutation
Updated: Jan 11, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Xanthomatous giant cell renal cell carcinoma: clinicopathologic and molecular characterization of 2 additional cases
Qiancheng Chen1,2, Heli Wang2, Suying Wang2
1Health Science Center, Ningbo University, Ningbo, China.
Objective:
To characterize the clinicopathologic, immunohistochemical, and molecular features of 2 new cases of xanthomatous giant cell renal cell carcinoma, a rare TSC2/MTOR-altered renal neoplasm.
Methods:
Both tumors underwent histologic evaluation, immunohistochemical profiling, and DNA-based targeted next-generation sequencing. Fluorescence in situ hybridization for TFE3 rearrangement was performed in 1 case.
Results:
Both patients were men (aged 27 and 64 years) with incidentally detected renal masses showing infiltrative growth and discohesive large cells with a xanthomatous-eosinophilic cytoplasm, basophilic stippling, vacuolization, and prominent nucleoli. Both tumors were positive for PAX8, CD10, vimentin, and GPNMB; keratin 20 was diffusely strong in 1 patient and isolated in the other. One case showed TFE3 and Melan-A coexpression without TFE3 rearrangement. Biallelic TSC2 mutations were identified in both cases, corroborated by loss of TSC2 protein expression. Both patients were disease-free at 15 and 40 months postsurgery.
Conclusions:
Xanthomatous giant cell renal cell carcinoma represents a distinct morphologic variant of TSC/MTOR-altered renal neoplasms with indolent behavior despite aggressive histologic features.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...